Rare subtypes of adenocarcinoma of the lung

Expert Review of Anticancer Therapy

Volumn 11, Issue 10, 2011, Pages 1535-1542

  Ou, Sai Hong Ignatius ^a   Kawaguchi, Tomoya ^b   Soo, Ross A ^c   Kitaichi, Masanori ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

adenocarcinoma; bronchioloalveolar carcinoma; colloid adenocarcinoma; driver mutation; enteric (intestinal type) adenocarcinoma; fetal adenocarcinoma; IASLC ATS ERS classification (2011); invasive mucinous adenocarcinoma; lung cancer; molecular pathway; molecular profiling; non small cell lung cancer; signet ring adenocarcinoma; WHO classification (1999)

Indexed keywords

ARTICLE; CANCER CLASSIFICATION; CANCER MORPHOLOGY; CLEAR CELL CARCINOMA; COLLOID ADENOCARCINOMA; CYSTADENOCARCINOMA; ENTERIC ADENOCARCINOMA; FETAL ADENOCARCINOMA; HUMAN; INTERMETHOD COMPARISON; INTERNATIONAL CLASSIFICATION OF DISEASES; INVASIVE MUCINOUS ADENOCARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; RARE DISEASE; SIGNET RING CARCINOMA;

ADENOCARCINOMA; HUMANS; LUNG NEOPLASMS; NEOPLASM INVASIVENESS; RARE DISEASES;

EID: 80054722124     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.99     Document Type: Article

References (27)

1. WHO. Histological typing of Lung and Pleural Tumors (3rd edition). Travis WD, Colby TV, Corrin B et al. (Eds). Springer-Verlig Berlin, Germany (1999).
2. Travis WD, Brambilla E, Noguchi M et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classifcation of lung adenocarcinoma. J. Thorac. Oncol. 6, 244-285 (2011).
3. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to geftinib. N. Engl. J. Med. 350, 2129-2139 (2004). (Pubitemid 38637993)
4. Finberg KE, Sequist LV, Joshi VA et al. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar carcinoma. J. Mol. Diagn. 9, 320-326 (2007). (Pubitemid 47305068)
5. Sakuma Y, Matsukuma S, Yoshihara M et al. Distinctive evolution of nonmucinous and mucinous bronchioloalveolar carcinoma in EGFR and KRAS gene-mutation analyses for Japanese lung adenocarcinomas. Confrmation of the correlations with histologic subtypes and gene mutations. Am. J. Clin. Pathol. 128, 100-108 (2007). (Pubitemid 47121721)
6. Rossi GR, Murer B, Cavazza A et al. Primary mucinous (so-called colloid) carcinomas of the lung: a clinicopathologic and immunohistochemical study with special reference to CDX2 homeobox gene and MUC2 expression. Am. J. Surg. Pathol. 28, 442-452 (2004). (Pubitemid 38436517)
7. Takao M, Takagi T, Suzuki H et al. Resection of mucinous adenocarcinoma presenting with intractable bronchorrhea. J. Thorac. Oncol. 5, 576-578 (2010).
8. Sato S, Koike T, Yamato Y et al. Resected well-differentiated fetal pulmonary adenocarcinoma and summary of 25 cases in Japan. Jpn. J. Thorac. Cardiovas. 54, 539-542 (2006). (Pubitemid 46154117)
9. Koss MN, Hochholzer L, O'Leary T Pulmonary blastomas. Cancer 67, 2368-2381(1991).
10. Sekine S, Shibata T, Matsuno Y et al. p-catenin mutations in pulmonary blastomas: association with morule formation. J. Pathol. 200, 214-221 (2003). (Pubitemid 36748030)
11. Yousem SA. Pulmonary intestinal-type adenocarcinoma does not show enteric differentiation by immunohistochemical study. Modern Pathol. 18, 816-821 (2005). (Pubitemid 40780515)
12. Inamura K, Satah Y, Okumura S et al. Pulmonary adenocarcinomas with enteric differentiation. Histologic and immunohistochemical characteristics compared with metastatic colorectal cancers and usual pulmonary adenocarcinomas. Am. J. Surg Pathol. 29, 660-665 (2005). (Pubitemid 40577877)
13. Li HC, Schmidt L, Greenson JK et al. Primary pulmonary adenocarcinoma with intestinal differentiation mimicking metastatic colorectal carcinoma. Am. J. Clin. Pathol. 131, 129-133 (2009).
14. Katzenstein AA, Prioleau PG, Askin FB. The histologic spectrum and signifcance of clear-cell change in lung carcinoma. Cancer 45, 943-947 (1980). (Pubitemid 10129845)
15. Rodig SJ, Mino-Kenudson M, Dacic S et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin. Cancer Res. 15, 5216-5223 (2009).
16. Shaw AT, Yeap BY, Mino-Kneudson M et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 27, 4247-4253 (2009).
17. Yoshida A, Tsuta K, Watanabe SI et al. Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component. Lung Cancer 72, 309-351 (2011).
18. Ou S-HI, Ziogas A, Zell JA. Primary signet-ring carcinoma (SRC) of the lung. A population-based epidemiologic study of 262 cases with comparison to adenocarcinoma of the lung. J. Thorac. Oncol. 5, 420-427 (2010).
19. Sun Y, Ren Y, Fang Z et al. Lung adenocarcinoma from East Asia never-smokers is a disease largely defned by targetable oncogenic mutant kinases. J. Clin. Oncol. 28, 4616-4620 (2010).
20. Marchetti A, Felicioni L, Malatesta S et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J. Clin. Oncol. 29, 3574-3579 (2011).
21. Rikova K, Guo A, Zeng Q et al. Global survey of phosphotyrosine signaling identifed oncogenic kinases in lung cancer. Cell 131, 1190-1203 (2007). (Pubitemid 350235027)
22. Soda M, Choi YL, Enomoto M et al. Identifcation of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566 (2007). (Pubitemid 47206930)
23. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12, 175-180 (2011).
24. Kwak EL, Bang Y-J, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
25. Maemondo M, Inoue A, Kobayashi K et al. Geftinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380-2388 (2010).
26. Sequist LV, Waltman BA, Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011).
27. Maheswaran S, Sequist LV, Nagrath S et al. Detection of mutations in EGFR circulating lung-cancer cells. N. Engl. J. Med. 359, 366-377 (2008).